SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Intercept Pharmaceuticals, Inc. 
 NJ
  SEC # 1270073


        
    Click to view...      Registrant      About      Filings      Files      Relationships      Names    
  Topics  
    Web       

149  Topics
Topic emoji
 within the 

Show:   Most-Recent Document   All Documents   And:   Exhibits  

 As Of  Filing  Doc.  Page    Title Docs.
  In ascending order
5/1/23DEF 14A1Additional Corporate Policies
1Administrator; Awards Available Under the Plan
1Amendments
1Annual Meeting Matters
1Appendix: 2023 Equity Incentive Plan
1Audit Committee
1Audit Committee Report
1Board Attendance at Annual Meetings of Stockholders
1Board Leadership Structure
1Board of Directors and Governance
1Board Oversight of Risk
1Cautionary Note Regarding Forward-Looking Statements
1Certain Federal Income Tax Consequences in Respect of the Plan
1Committees of the Board
1Communication with the Board
1Compensation Committee
1Compensation Committee Report
1Compensation Discussion and Analysis
1Composition of the Board
8/2/2310-Q1Condensed Consolidated Balance Sheets at June 30, 2023 and December 31, 2022 (Unaudited)
4/27/2310-Q1Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022 (Unaudited)
11/6/2310-Q1Condensed Consolidated Balance Sheets at September 30, 2023 and December 31, 2022 (Unaudited)
1Condensed Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2023 and 2022 (Unaudited)
8/2/2310-Q1Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2023 and 2022 (Unaudited)
4/27/2310-Q1Condensed Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2023 and 2022 (Unaudited)
11/6/2310-Q1Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and nine-month periods ended September 30, 2023 and 2022 (Unaudited)
8/2/2310-Q1Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and six-month periods ended June 30, 2023 and 2022 (Unaudited)
4/27/2310-Q1Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three-month periods ended March 31, 2023 and 2022 (Unaudited)
11/6/2310-Q1Condensed Consolidated Statements of Comprehensive (Loss) Income for the three and nine-month periods ended September 30, 2023 and 2022 (Unaudited)
8/2/2310-Q1Condensed Consolidated Statements of Comprehensive Loss for the three and six-month periods ended June 30, 2023 and 2022 (Unaudited)
4/27/2310-Q1Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 2023 and 2022 (Unaudited)
11/6/2310-Q1Condensed Consolidated Statements of Operations for the three and nine-month periods ended September 30, 2023 and 2022 (Unaudited)
8/2/2310-Q1Condensed Consolidated Statements of Operations for the three and six-month periods ended June 30, 2023 and 2022 (Unaudited)
4/27/2310-Q1Condensed Consolidated Statements of Operations for the three-month periods ended March 31, 2023 and 2022 (Unaudited)
11/6/2310-Q1Controls and Procedures
5/1/23DEF 14A1Corporate Governance
1Director Compensation
1Employment Arrangements with Our NEOs
1Equity Compensation Plan Information
1Equity Plan Is Necessary and Appropriate, The
1Esg
1Executive Compensation
1Executive Officers
1Executive Sessions
11/6/2310-Q1Exhibit Index
1Exhibits
5/1/23DEF 14A1Expenses and Solicitation
1Fees Paid to KPMG LLP
11/6/2310-Q1Financial Statements
5/1/23DEF 14A1General Information About the Annual Meeting and Voting
1Global Code of Business Conduct
1Grants of Plan-Based Awards Table
1Householding
1Independence
1Independent Registered Public Accounting Firm
11/6/2310-Q1Item 1
1Item 1A
1Item 2
1Item 3
1Item 4
1Item 5
1Item 6
1Legal Proceedings
5/1/23DEF 14A1Limitation on Liability and Indemnification Matters
11/6/2310-Q1Management's Discussion and Analysis of Financial Condition and Results of Operations
5/1/23DEF 14A1New Plan Benefits
1Nominating and Governance Committee
11/6/2310-Q1Notes to Condensed Consolidated Financial Statements (Unaudited)
5/1/23DEF 14A1Other Business
1Other Disclosures
11/6/2310-Q1Other Information
5/1/23DEF 14A1Other Provisions
1Outstanding Equity Awards at Fiscal Year-End
1Overview
11/6/2310-Q1Part I Financial Information
1Part Ii
5/1/23DEF 14A1Pay Ratio Disclosure
1Pay Versus Performance Disclosure
1Plan Features
1Plan Participants
1Plan Size and Term
1Potential Payments and Benefits Upon Termination of Employment or Change in Control
1Pre-Approval Policy and Procedures
1Proposal 2: Approval of Our 2023 Equity Incentive Plan
1Proposal 3: Non-Binding, Advisory Vote on the Compensation of the Company's Named Executive Officers
1Proposal 4: Ratification of Appointment of Independent Registered Public Accounting Firm
1Proposals 1A Through 1K: Election of Directors
1Proposals Under Vote
1Purpose
11/6/2310-Q1Quantitative and Qualitative Disclosures About Market Risk
5/1/23DEF 14A1Related Person Transactions
1Research and Development Committee
11/6/2310-Q1Risk Factors
5/1/23DEF 14A1Role and Meetings of the Board
1Security Ownership of Certain Beneficial Owners and Management
11/6/2310-Q1Signatures
5/1/23DEF 14A1Stock Ownership Guidelines for Directors
1Stockholders' Proposals
1Summary Compensation Table
1Summary of Material Terms of the Plan
11/6/2310-Q1Table of Contents
5/1/23DEF 14A1Table of Option Exercises and Stock Vested
1The Equity Plan Is Necessary and Appropriate
8/2/2310-Q1Unregistered Sales of Equity Securities and Use of Proceeds
11/6/2310-Q1Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities
5/1/23DEF 14A1Vote Required for Approval

Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 9, 5:18:31.2pm ET